(ABBV)

The three pharma stocks in this analysis all look a bit mixed in the premarket, after seeing some momentum late last week. This is especially true with LLY, as you will see on the charts.

It's been a stomach-churning past few months for investors in pharmaceutical giant AbbVie (ABBV 0.62%). A potential blockbuster drug that AbbVie spent roughly $9 billion to acquire the rights to faile...

AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Investors love dividend stocks, especially the high-yield variety, because they offer a significant income stream and have massive total return potential.

March investments totaled around $1,200, mainly in BDCs like Blue Owl Capital and Ares Capital, boosting annual dividend income by $100. Dividend income hit a new all-time record of $1,404, up 17% Y/Y...

NEW YORK, NY / ACCESS Newswire / April 16, 2025 / If you suffered a loss on your Cerevel Therapeutics Holdings, Inc. (NYSE:ABBV) investment and want to learn about a potential recovery under the feder...

AbbVie, The TJX, The Charles Schwab, Enzo Biochem and CVD Equipment are included in this Analyst Blog.

In my 2025 Outlook, I picked AbbVie Pharmaceuticals (NYSE: ABBV) as one to watch this year. Here is what I wrote: AbbVie (ABBV) AbbVie primarily works in immunology, oncology, neuroscience, eye care, ...

Merck and AbbVie are included in this Analyst Blog.